Cardiex Ltd (CDX) - Total Assets
Based on the latest financial reports, Cardiex Ltd (CDX) holds total assets worth AU$16.99 Million AUD (≈ $12.02 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CDX cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cardiex Ltd - Total Assets Trend (2002–2024)
This chart illustrates how Cardiex Ltd's total assets have evolved over time, based on quarterly financial data. Explore CDX long-term investments to assets to see how much of total assets are deployed in long-term investments.
Cardiex Ltd - Asset Composition Analysis
Current Asset Composition (June 2024)
Cardiex Ltd's total assets of AU$16.99 Million consist of 82.0% current assets and 18.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 3.8% |
| Accounts Receivable | AU$350.99K | 2.8% |
| Inventory | AU$2.55 Million | 20.2% |
| Property, Plant & Equipment | AU$1.22 Million | 9.6% |
| Intangible Assets | AU$619.70K | 4.9% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Cardiex Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CDX market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cardiex Ltd's current assets represent 82.0% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2024, down from 42.5% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 10.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 20.2% of total assets.
Cardiex Ltd Competitors by Total Assets
Key competitors of Cardiex Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Inspire Medical Systems Inc
NYSE:INSP
|
USA | $911.38 Million |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥1.59 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Stratec SE
XETRA:SBS
|
Germany | €443.38 Million |
|
Scandinavian Medical Solutions AS
CO:SMSMED
|
Denmark | Dkr205.86 Million |
|
Duearity AB
ST:DEAR
|
Sweden | Skr10.84 Million |
Cardiex Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.48 | 1.02 | 1.29 |
| Quick Ratio | 1.23 | 0.85 | 1.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$4.75 Million | AU$321.84K | AU$1.05 Million |
Cardiex Ltd - Advanced Valuation Insights
This section examines the relationship between Cardiex Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.34 |
| Latest Market Cap to Assets Ratio | 1.05 |
| Asset Growth Rate (YoY) | -11.6% |
| Total Assets | AU$12.65 Million |
| Market Capitalization | $13.23 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cardiex Ltd's assets above their book value (1.05x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Cardiex Ltd's assets decreased by 11.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cardiex Ltd (2002–2024)
The table below shows the annual total assets of Cardiex Ltd from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | AU$12.65 Million ≈ $8.95 Million |
-11.55% |
| 2023-06-30 | AU$14.30 Million ≈ $10.12 Million |
+15.55% |
| 2022-06-30 | AU$12.38 Million ≈ $8.76 Million |
+9.89% |
| 2021-06-30 | AU$11.26 Million ≈ $7.97 Million |
+5.52% |
| 2020-06-30 | AU$10.68 Million ≈ $7.55 Million |
-19.20% |
| 2019-06-30 | AU$13.21 Million ≈ $9.35 Million |
+105.99% |
| 2018-06-30 | AU$6.41 Million ≈ $4.54 Million |
+116.68% |
| 2017-06-30 | AU$2.96 Million ≈ $2.09 Million |
-35.70% |
| 2016-06-30 | AU$4.60 Million ≈ $3.26 Million |
-22.68% |
| 2015-06-30 | AU$5.95 Million ≈ $4.21 Million |
+28.55% |
| 2014-06-30 | AU$4.63 Million ≈ $3.28 Million |
-27.35% |
| 2013-06-30 | AU$6.38 Million ≈ $4.51 Million |
+52.45% |
| 2012-06-30 | AU$4.18 Million ≈ $2.96 Million |
-20.37% |
| 2011-06-30 | AU$5.25 Million ≈ $3.72 Million |
-11.01% |
| 2010-06-30 | AU$5.90 Million ≈ $4.18 Million |
-25.30% |
| 2009-06-30 | AU$7.90 Million ≈ $5.59 Million |
-0.64% |
| 2008-06-30 | AU$7.95 Million ≈ $5.63 Million |
-30.28% |
| 2007-06-30 | AU$11.40 Million ≈ $8.07 Million |
-28.03% |
| 2006-06-30 | AU$15.85 Million ≈ $11.21 Million |
-22.08% |
| 2005-06-30 | AU$20.34 Million ≈ $14.39 Million |
+518.87% |
| 2004-06-30 | AU$3.29 Million ≈ $2.33 Million |
+113.10% |
| 2003-06-30 | AU$1.54 Million ≈ $1.09 Million |
-1.03% |
| 2002-06-30 | AU$1.56 Million ≈ $1.10 Million |
-- |
About Cardiex Ltd
Conneqt Health Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffnes… Read more